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PREVENTION AND REVERSAL OF LUPUS IN NZB/NZW MICE BY TRANS-
PLANTATION OF PURIFIED ALLOGENEIC HEMATOPOIETIC STEM CELLS
(HSC) WITH NON-MYELOABLATIVE CONDITIONING (NMT)
Smith-Berdan, S.1, Gille, D.1, Christensen, J.L.1 1Cellerant Therapeu-
tics, San Carlos, CA.
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune
disease. Patients’ refractory to therapy may be considered for hema-
topoietic stem cell transplantation. Using lupus prone NZB x NZW
(NZBW) mice, we tested the ability of highly enriched, allogeneic
haplo-identical HSC to prevent and reverse autoimmune symptoms.
Ablative conditioning: Young, female NZBW mice were trans-
planted with puriﬁed haplo-identical allogeneic HSC, syngeneic HSC
or syngeneic WBM from age matched donors. Transplantation with
either syngeneic HSC or WBM accelerated disease in these mice,
resulting in a rate of death exceeding agematched controls. Allogeneic
transplanted mice had signiﬁcantly greater overall survival (OS) above
all groups (P 0.0243), with 53% alive at 420 days of age. The
frequency of mice with proteinuria (14%), elevated levels of circulat-
ing immune complexes (CIC) (25%), and auto-antibodies to dsDNA
(39%), nuclear antigens (39%) and histones (46%) was lower in
allo-HSC transplanted animals compared to the mice transplanted
with syngeneic HSC or WBM and the age matched controls (74-
100%) (P 0.0001). NMT conditioning: To determine if we could
attenuate disease in NZBW mice already progressing into lupus-like
disease with transplantation of allogeneic, haplo-identical HSC and
reduce TRM, we developed a non-myeloablative conditioning proto-
col achieving an average mixed chimerism of 50%. Animals were
treated at 8 months of age with established symptoms of lupus (Table
1). While the group receiving conditioning alone, had a slight survival
advantage over age matched control mice, the mice transplanted with
allogeneicHSC had greatly increasedOSwith 60% living beyond 575
days of age (335 days from transplant). Allo-HSC transplanted mice
showed reversal or stabilization of their lupus symptoms including
proteinuria, CIC, dsDNA and histone. Conclusions: 1) Ablative and
NMT transplant can treat lupus; 2) OS after NMT exceeds ablative
conditioning; 3) Induction of durable mixed chimerism with puriﬁed
allogeneic HSC using NMT conditioning treats established lupus.
The ability of pure HSC transplant and establishment of durable
mixed chimerism to reverse established lupus makes it a reasonable
strategy to test in man.
Summary of survival, proteinuria & serology with NMT conditioning
NMT age@Tx241
days
Age
matched
control
Allogeneic
HSC
Conditioning
only
N 13 33 30
OS@0575 days of age 0 60% 0
Proteinuria@Tx 22% 45% 47%
Final Proteinuria 100% 30% 70%
CIC 89% 52% 73%
Anti-dsDNA 86% 55% 70%
Anti-Histone 100% 36% 62%
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NOD FC EXHIBIT SIGNIFICANTLY IMPAIRED FUNCTION
Fugier-Vivier, I.J.1, Huang, Y.1, Miller, T.1, Tanner, M.K.1,
Chilton, P.M.1, Ildstad, S.T.1 1Institute for Cellular Therapeutics, Uni-
versity of Louisville, Louisville, KY.
Induction of mixed allogeneic chimerism in humans and in pre-
diabetic NOD mice reverses the autoimmune process in type 1
diabetes. The administration of Flt3-ligand (FL) to NOD mice
decreases diabetes incidence and delays the onset of diabetes. One
mechanism by which both chimerism and FL treatment may re-
verse autoimmunity is through generation of dendritic cell (DC)
subsets lacking in NOD mice. In the present studies we character-
ized NOD FC function, comparing the ability of diabetes-resistant
NOR FC versus NOD FC to enhance NOD HSC engraftment in
NOD recipients. 500 NOD HSC (c-Kit/Sca-1/Lin-) were
sorted and transplanted with 30,000 NOR FC (HSCFC group,
n15) or without FC (HSC group, n21) into conditioned 950
cGy NOD recipients. The NOR FC strongly increased NOD
HSC engraftment compared to the HSC group alone (p  0.001).
By contrast, NOD FC did not improve NOD HSC engraftment in
NOD recipients as evidenced by the similar engraftment of 500
HSC with 30,000 FC (HSCFC group, n13) compared to the
NOD HSC group (n17). These results point without ambiguity
to a defect in NOD FC that is not present in the NOR FC. To
characterize the defect in the NOD FC population, we explored
the difference between NOD FC and functional NOR or B6 FC
composition of FC subpopulations. CD8/TCR- NOD FC were
sorted from bone marrow and the sorted FC were evaluated for
subpopulations we previously found in normal FC: NK cells
(DX5), myeloid cells (CD11b), B cells (CD19), monocytes (CD14),
and dendritic cells (CD11c). We found that precursor plasmacy-
toid dendritic cells (p-pre DC FC) represented the major FC
subpopulation in all strains examined. Interestingly, only the CD19
FC subpopulation was signiﬁcantly decreased in NOD FC com-
pared to those from B6 or NOR mice (12% versus 26%, P 0.05
from more than three separate experiments on 3-5 mice). From our
results, we hypothesize that the CD19 FC subpopulation could
represent the collaborative cell within the FC population that
synergizes with the p-preDC FC to provide an optimal facilitating
effect. Studies are in progress to determine whether FL-treatment
restores the CD19 FC population in NOD mice and determine
whether FL-treated NOD FC recover the ability to enhance HSC
engraftment. Our underlying hypothesis is that restoring function
to NOD FC will provide the milieu to induce the otherwise lacking
regulatory mechanisms and control the autoimmunity in diabetes.
Group HSC donor FC donor n
% survival over
120 days post
Tx
A NOD none 38 21
B NOD NOD 13 31
C NOD NOR 15 53
D none none 15 0
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) FOR AUTOIM-
MUNE DISEASES (AI): REVIEW OF TRANSPLANTS PERFORMED IN
NORTH AND SOUTH AMERICA AND REPORTED TO THE CENTER FOR
INTERNATIONAL BLOOD AND MARROW TRANSPLANTATION (CIBMTR)
Mcsweeney, P.A.1,5, Pasquini, M.C.2, Kukreja, M.2, Bredeson, C.2,
Nash, R.3, Horowitz, M.M.2, Atkins, H.4 1US Oncology Rocky Moun-
tain Cancer Center, Denver, CO; 2Medical College of Wisconsin, Mil-
waukee, WI; 3Fred Hutchinson Cancer Research Center, Seattle, WA;
4Otawa Hospital, Otawa, ON, Canada; 5on behalf of the CIBMTR
Autoimmune Working Committee.
The objective of high dose chemotherapy followed by hemato-
poietic stem cell rescue is to halt autoimmunity in patients with
severe AI. Few patients have received this treatment to date and
this report summarizes the activity of HCT for AI from centers in
North and South America. One-hundred and ninety-eight patients
who underwent HCT primarily for the treatment of AI, were
reported to the CIBMTR from 1996-2005 from 43 centers. Most
received an autologous HCT (autoHCT) (171 of 198). The most
common indications for autoHCT were multiple sclerosis (MS)
(45%), scleroderma (SSC) (35%) and systemic lupus erythematous
34
(SLE) (8%). Twenty-seven patients received allogeneic HCT (al-
loHCT) for SSC (n7), amyotrophic lateral sclerosis (n6), au-
toimmune cytopenias (n6), SLE (n2), autoimmune enteropathy
(n1) and unclassiﬁed AI (n3). The median age at HCT did not
differ by transplant type (41 vs. 36 years for autoHCT and allo-
HCT, respectively) and most patients (66%) had a good perfor-
mance score at HCT. The median time from diagnosis to trans-
plant was 58 and 34 months for autoHCT and alloHCT,
respectively. Irradiation-containing conditioning regimens were
used in 109 cases (61%) and cyclophosphamide either alone or in
combination with other agents without irradiation in 45 cases
(25%). Most autoHCT recipients received total body irradiation,
cyclophosphamide and anti-thymocyte globulin (64%). Peripheral
stem cell cells were the predominant graft type; and 56% of these
grafts were manipulated ex vivo (CD34 cell selection or T-cell
depletion). The probabilities of 100-day mortality were 10% (95%
conﬁdence interval [CI], 6-15%) and 17% (95% CI, 5-35%) after
autoHCT and alloHCT, respectively. Corresponding one-year
probabilities of overall survival were 89% (95% CI, 83-93%) and
75% (95% CI, 54-91%). One-year probability of overall survival
post-autoHCT were 96%, 82% and 73% for MS, SSC and SLE
respectively. In summary, these collective data from CIBMTR, MS
and SSC are the most common autoimmune disease indications for
HCT.
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AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AH-
SCT) FOR EARLY ONSET TYPE I DIABETES MELLITUS
Moraes, D.A.1, Oliveira, M.C.1, Stracieri, A.B.1, Couri, C.E.1,
Barros, G.M.1, Pieroni, F.1, Coutinho, M.A.1, Foss, M.C.1,
Simoes, B.P.1, Voltarelli, J.C.1 1Hospital das Clinicas/University of Sao
Paulo, Ribeirao Preto, Sa˜o Paulo, Brazil.
Introduction: Type I Diabetes mellitus (DM1) is an autoim-
mune disease that destroys pancreatic islet cells were insulin is
producted, leading to insulin dependence and chronic complica-
tions such as retinopathy, nephropathy, neuropathy and coronary
atherosclerosis.
Objectives: Evaluate the efﬁcacy and toxicity (phases I/II) of
high-dose cyclophosphamide (Cy) and rabbit anti-thymic globulin
(rATG) followed by rescue with AHSCT in patients with less than
6 weeks from diagnosis of type 1 Diabetes mellitus.
Materials and Methods: Stem cells were mobilized from the
bone marrow with Cy (2g/m2) and Filgrastim (10g/kg/d SC),
collected by leukapheresis and cryopreserved. Patients were con-
ditioned with Cy (50mg/kg x 4) and rATG (4.5 mg/kg), followed
by stem cell infusion.
Results: Since December 2003, 15 patients were enrolled in this
study. The medium age was 19.2 years, (14- 31 years), and the time
between diagnosis and mobilization was 34.7 days (24 to 49 days).
The mean hospitalization period was 24,2 days (16- 57 days) and
the average number of CD34 infused cells was 10.8106/kg
(5.8- 23.19106/kg). Neutrophil engrafted on days 8 to 10 (aver-
age of 9,3 days) and platelets engrafted on days 0 to 15 days
(average 12.3 days). There were no deaths. Most patients had
neutropenic fever, but only one developed serious complications
needing intensive care due to bilateral pneumonia, reversed with
antibiotic therapy and non-invasive ventilation. All patients were
using exogenous insulin therapy before mobilization, with an av-
erage dose of 0.38 Ul/kg (0.13 to 0.58 Ul/kg). In a mean follow-up
of 14.2 months (1- 31 months), insulin therapy was suspended in 12
patients from D-7 to D39 (average 32), two patients decreased
insulin dose (16 and 21% compared to the period before AHSCT)
and one patient remains using high dose insulin (1.7 Ul/kg/d). This
last patient was the only one that presented ketoacidosis pre-
AHSCT and received corticosteroids in the pre-conditioning pe-
riod. Six to twelve months after AHSCT, the peptide-C levels
considerably increased in 7 patients with clinical response and
glycated hemoglobin values are 7%.
Conclusion: These results indicate that high-dose immunosup-
pression associated with AHSCT may induce prolonged clinical
remission of Type 1 diabetes mellitus, without signiﬁcant toxicity.
The durability of response will be evaluated in longer follow-up.
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SERIAL SKIN BIOPSIES DEMONSTRATE REDUCED DERMAL FIBROSIS
AFTER AUTOLOGOUS HEMOPOIETIC STEM CELL TRANSPLANT (A-
HSCT) FOR SEVERE SYSTEMIC SCLEROSIS (SSS)
Shulman, H.M.1, Nash, R.A.1 1Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA.
Background: In a multiinstitutional study, 34 patients with SSS
received high-dose immunosuppressive therapy followed by A-
HSCT. Serial evaluations included improvement in the modiﬁed
Rodnan skin score (mRSS, 51-0) and histologic dermal ﬁbrosis
score (DFS), grades 0-5.
Methods: 10 patients had 23 pre and post HSCT serial biopsies,
mean follow-up 4 years. Punch biopsies from each patient were
obtained from the same location on the lateral upper or lower arm.
The DFS was based on the depth and % of dermal homogeniza-
tion, size orientation and eosinophilia of ﬁbers, and interstitial
space between the fascicles in H&E -stained sections. The mRSS
showed a signiﬁcant improvement in 8/10 patients. The mean
decrease in mRSS of 34 patients’ (baseline 30.2) to ﬁnal evaluation
was 22.08 (-70.3%, and with a signiﬁcant linear decrease over time,
both p   0.0001). The DFS in 7 of 10 had 3 grades of
reduction. 3 had a ﬁnal DFS of 0 with reduction of dermal thick-
ness, loss of homogenization thinning and straightening of the
collagen bundles with an increase in interstitial space. The dermal-
epidermal border remained straightened with loss of rete ridges
and loss of elastica in the papillary dermis. The discordant ﬁnal
scores in patient 8, decrease in DFS without decrease in mRSS was
likely related to localized improvement of skin at site of biopsy.
Conclusion:
A-HSCT for SSS leads to remodeling of dermal collagen with
loss of sclerosis and corresponding improvements in the mRSS.
RESULTS: Assessment of dermal ﬁbrosis after A-HSCT for SSS
Patient
Baseline Final Score
mRSS/DFS Year/mRss/DFS
1 35/3 2/3/1
2 16/3 6/0/0
3 40/5 5/10/0
4 26/4 1/18/3
5 19/4 5/1/1
6 20/5 4/7/3
7 30/4 4/8/0
8 48/5 4/42/1*
9 44/5 4/10/1
10 29/5 3/12/2
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PREVENTION OF MUCOSITIS IN AUTO BMT/STEM CELL TRANSPLANT
PATIENTS
Klocke, J.1, Cannon, M.1, Gissenger, D.1, Devoe, C.1, John, V.1,
Bayer, R.-L.1 1North Shore University Hospital, 300 Community
Drive, Manhasset, NY.
It is estimated that 80% of patients who undergo high-dose
chemotherapy plus or minus radiotherapy prior to transplantation
develop mucositis. Mucositis is a painful complication, which can
lead to poor nutrition, increased use of narcotics, dehydration,
greater risk for infection and bacteremia, as well as altered quality
of life. Patients can have oral ulceration, epigastric discomfort,
diarrhea, rectal irritation, and bleeding. It is likely that the com-
plications of mucositis can contribute to increased lenght of stay
during stem cell transplantation.
The purpose of this study is to compare patients who received
Kepivance(palifermin) as part of their treatment with patients that
did not receive this medication during autologous stem cell trans-
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